List of Excipients in Branded Drug SCANDONEST PLAIN

« Back to Dashboard

Generic Drugs Containing SCANDONEST PLAIN

Company	Ingredient	NDC	Excipient
Novocol Pharmaceutical of Canada Inc	mepivacaine hydrochloride	51004-1098	SODIUM CHLORIDE
Novocol Pharmaceutical of Canada Inc	mepivacaine hydrochloride	51004-1098	WATER

What are the Most Frequently-Used Excipients in SCANDONEST PLAIN?

# Of NDCs	Excipient
1	SODIUM CHLORIDE
1	WATER

Scandonest Plain Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Scandonest Plain is a preservative-free, vasoconstrictor-free injectable dental anesthetic containing 3% mepivacaine hydrochloride. Its commercial value is driven less by active-ingredient exclusivity and more by formulation simplicity, sterile manufacturing, cartridge performance, supply reliability, and differentiation for patients who should avoid sulfites or vasoconstrictors.

The core excipient strategy is intentionally narrow: sodium chloride for tonicity, water for injection as the vehicle, and pH adjustment within the product specification. A reformulator should avoid adding antioxidants, antimicrobial preservatives, or vasoconstrictors because those ingredients would weaken the product's principal clinical positioning.

What is the formulation of Scandonest Plain?

Scandonest Plain 3% contains 54 mg of mepivacaine hydrochloride in a 1.8 mL dental cartridge. The formulation uses a low-excipient aqueous system without epinephrine or another vasoconstrictor.

Attribute	Scandonest Plain 3%
Active ingredient	Mepivacaine hydrochloride
Strength	30 mg/mL, equivalent to 54 mg per 1.8 mL cartridge
Dosage form	Sterile injectable dental solution
Route	Submucosal dental injection
Vasoconstrictor	None
Preservative	None
Antioxidant	None identified in the US product labeling
Principal excipients	Sodium chloride and water for injection
Container	Single-use dental cartridge
Key formulation requirement	Sterility, clarity, controlled pH, acceptable tonicity, low particulate burden

The US labeling identifies sodium chloride and water for injection as inactive ingredients and specifies a controlled acidic pH range. The product is intended for infiltration and nerve-block anesthesia in dentistry. [1]

Why does Scandonest Plain exclude epinephrine?

Mepivacaine has useful intrinsic local-anesthetic activity and is marketed in a plain formulation for situations in which a vasoconstrictor is undesirable. Epinephrine can increase duration and reduce systemic absorption, but it can also create clinical concerns involving cardiovascular stimulation, drug interactions, and sensitivity to sulfite antioxidants used in some epinephrine-containing formulations.

Scandonest Plain's absence of epinephrine creates a clear commercial position:

• Patients for whom vasoconstrictors are clinically unsuitable.
• Dental procedures requiring a short- to moderate-duration anesthetic.
• Practices seeking a sulfite-free local anesthetic option.
• Formulary portfolios that need both plain and vasoconstrictor-containing anesthetics.

Which excipients are commercially important in Scandonest Plain?

The excipient system has limited room for expansion. Each ingredient must support a specific quality attribute without creating new toxicological, compatibility, or regulatory risks.

Sodium chloride

Sodium chloride supports isotonicity and injection comfort. Its concentration must be balanced against the hydrochloride salt form of mepivacaine, the final pH, and the volume delivered through the dental cartridge.

A generic or line-extension manufacturer should not assume that sodium chloride can be replaced freely by another tonicity agent. Dextrose, mannitol, or other osmotic agents could introduce new issues involving:

• Injection-site tolerability.
• Chemical stability.
• Container interaction.
• Osmolality variation.
• Comparative quality requirements.
• Labeling complexity.

Maintaining sodium chloride is commercially attractive because it preserves a familiar, low-risk excipient profile.

Water for injection

Water for injection is the vehicle and supports a simple sterile aqueous manufacturing process. The main commercial risks are not excipient novelty but microbial control, endotoxin management, particulate control, and container-closure integrity.

pH-adjusting agents

The label identifies a controlled pH range. Manufacturing may use acid or base adjustment to achieve the approved specification, even where those materials are not emphasized as formulation components in commercial descriptions.

pH is a critical quality attribute because it affects:

• Mepivacaine chemical stability.
• Injection-site comfort.
• Solution clarity.
• Container compatibility.
• Sterilization tolerance.
• Shelf life.

A reformulator should establish a narrow process target rather than operate close to the permitted specification limits.

What excipients should a reformulator avoid?

The strongest commercial strategy is usually to preserve the existing minimal formulation rather than add ingredients.

Antioxidants

Sodium metabisulfite and related sulfites are commonly associated with formulations containing epinephrine because they protect the vasoconstrictor from oxidation. They are unnecessary in a plain mepivacaine formulation and could undermine a sulfite-free product position.

Antimicrobial preservatives

Benzyl alcohol, parabens, chlorobutanol, and related preservatives would conflict with the single-use cartridge format and could create toxicological or labeling concerns. Dental cartridges are designed for single-patient administration, so multidose preservation is not a compelling value proposition.

Vasoconstrictors

Adding epinephrine would create a different product rather than a meaningful Scandonest Plain formulation improvement. It would alter clinical positioning, dosing considerations, stability requirements, antioxidant needs, and potentially the regulatory product classification.

Complex buffering systems

A heavily buffered formulation could improve pH control but may increase injection discomfort, introduce additional excipient exposure, and complicate comparability. The commercial benefit is limited unless the manufacturer can demonstrate a material improvement in stability or tolerability.

How strong is the formulation patent estate for Scandonest Plain?

Scandonest Plain is a legacy small-molecule injectable product. The active ingredient, mepivacaine hydrochloride, has been used in dentistry for decades. The commercial opportunity therefore does not depend on blocking patents covering the basic active ingredient.

IP category	Commercial relevance
Mepivacaine composition patents	Little practical relevance because the active ingredient is longstanding
Basic aqueous formulation patents	Likely limited value unless narrowly drafted and still enforceable
Epinephrine-containing formulations	Relevant to other products, not to plain Scandonest positioning
Dental cartridge and closure patents	Potentially relevant to manufacturing and device differentiation
Manufacturing process patents	Possible value for sterilization, filling, or container compatibility
Label or method-of-use patents	Limited value for established dental anesthesia indications
Trade secrets	Potential value in filling parameters, sterilization cycles, extractables control, and supplier qualification

A company should focus its freedom-to-operate review on current formulation, cartridge, stopper, crimp, filling, sterilization, and device patents rather than on the historical mepivacaine molecule.

Does Scandonest Plain have meaningful Orange Book protection?

The Orange Book framework provides little protection for a legacy mepivacaine product with no apparent current small-molecule exclusivity barrier. Mepivacaine hydrochloride is an established active ingredient, and generic competition is structurally possible through abbreviated or other applicable FDA pathways.

The relevant regulatory question is whether the reference product has current listed patents or exclusivity that would delay approval of a competing product. FDA's Orange Book should be reviewed for the current reference-product listing, patent certifications, and therapeutic-equivalence information. [2]

When does Scandonest Plain lose exclusivity?

Scandonest Plain's principal market exclusivity has effectively expired because mepivacaine hydrochloride is an old, established local anesthetic. Any current commercial protection is more likely to arise from:

• Brand recognition among dentists.
• Product availability.
• Cartridge compatibility.
• Manufacturing quality.
• Distributor relationships.
• Regulatory approvals in specific countries.
• Narrow device or packaging rights.
• Contractual supply arrangements.

The product should not be valued like a recently approved specialty drug. Its defensibility is operational and commercial rather than based on long-duration patent exclusivity.

What generic entry risks exist for Scandonest Plain?

Generic entry risk is high at the active-ingredient level but more moderate at the finished-product level. Injectable dental anesthetics require specialized manufacturing and distribution capabilities.

Paragraph IV challenges

A competitor seeking approval under the US abbreviated pathway could evaluate listed patents and submit the applicable certification, including a Paragraph IV certification if it asserts that a listed patent is invalid, unenforceable, or not infringed. Because the product is old and the core formulation is simple, a Paragraph IV challenge would be commercially credible if a current listed patent covered the reference product.

The most likely challenge targets would be:

• Formulation claims.
• Cartridge or container-closure claims.
• Manufacturing process claims.
• Narrow stability claims.

Basic claims to mepivacaine hydrochloride would have limited practical value if expired.

Generic launch scenarios

Scenario	Market effect
One approved generic	Price pressure, but brand may retain dental-practice accounts
Multiple cartridge suppliers	Higher substitution and contracting pressure
Generic with lower supply reliability	Brand retains share through availability
Generic with equivalent cartridge compatibility	Faster pharmacy and distributor substitution
Alternate vial or ampule presentation	Limited direct substitution in routine dentistry
Preservative-free, sulfite-free competitor	Direct pressure on Scandonest Plain's main differentiation

The largest threat is a competitor offering the same strength, same cartridge format, reliable supply, and equivalent preservative-free positioning.

What formulations could compete with Scandonest Plain?

Competition comes from both mepivacaine and other dental local anesthetics.

Product type	Commercial advantage	Limitation
Mepivacaine plain 3%	Similar clinical positioning and simple formulation	Direct price competition
Mepivacaine with levonordefrin	Longer duration and reduced systemic absorption	Vasoconstrictor-related restrictions
Lidocaine with epinephrine	Broad dentist familiarity and strong efficacy	Contains vasoconstrictor and antioxidant system
Articaine with epinephrine	Strong diffusion and broad dental use	Vasoconstrictor and sulfite exposure
Prilocaine with felypressin or other vasoconstrictor	Alternative pharmacology in some markets	Country-specific availability
Novel long-acting injectable anesthetic	Longer duration	Higher development cost and different safety profile

Scandonest Plain is most differentiated against epinephrine-containing products, not against another plain mepivacaine product.

What formulation improvements could create commercial opportunities?

Ready-to-use cartridge optimization

The most practical opportunity is an optimized cartridge system that preserves the formulation while improving handling. Potential improvements include:

• Lower breakage rates.
• Improved plunger glide.
• Better needle-interface compatibility.
• More consistent dose delivery.
• Enhanced tamper evidence.
• Improved visibility of the solution and fill volume.

These changes may support device or packaging claims even when the liquid formulation remains unchanged.

Enhanced stability and supply-chain performance

A reformulated or line-extended product could target:

• Longer shelf life.
• Greater temperature excursion tolerance.
• Reduced sensitivity to light.
• Lower particulate generation.
• Improved resistance to stopper interaction.
• More robust shipping performance.

The manufacturer must show that these benefits do not change mepivacaine assay, impurities, pH, sterility, endotoxin, or container-closure performance.

Alternate presentations

Potential presentations include:

• 1.8 mL standard cartridges.
• 2.2 mL cartridges for markets using larger dental volumes.
• Unit-dose ampules.
• Small-volume vials for institutional dentistry.
• Procedure-specific multipacks.
• Packaging designed for mobile or community dental clinics.

The commercial opportunity is highest where the presentation solves a workflow problem without weakening the established cartridge format.

Specialty positioning

The product can be positioned for:

• Patients requiring a vasoconstrictor-free anesthetic.
• Patients avoiding sulfite-containing products.
• Short dental procedures.
• Pediatric and geriatric dental settings, subject to approved labeling and dosing.
• Hospitals and clinics seeking a preservative-free local anesthetic.

Claims must remain within the approved labeling and applicable promotional rules. FDA local-anesthetic labeling emphasizes dose limits, systemic toxicity, injection technique, and patient-specific risk assessment. [1]

What manufacturing and IP barriers affect commercial entry?

The liquid formulation is simple, but sterile dental cartridges create meaningful technical barriers.

Sterile fill-finish

The product requires validated sterile processing, aseptic filling or an approved terminal sterilization approach, and control of:

• Bioburden.
• Endotoxin.
• Visible and subvisible particles.
• Fill volume.
• Container-closure integrity.
• Sterility over shelf life.

Cartridge compatibility

A manufacturer must qualify the glass cartridge, elastomeric plunger, diaphragm, aluminum seal, and dental syringe interface. Extractables and leachables are important because the formulation remains in contact with the primary container throughout its shelf life.

Supply chain

The commercial product depends on specialized suppliers for:

• Dental cartridges.
• Elastomeric components.
• Sterile filling.
• Packaging equipment.
• Dental distributors.
• International regulatory registrations.

A company with a reliable cartridge supply may compete effectively even without formulation patents.

What licensing deals could create value?

Licensing opportunities are more likely to involve manufacturing and distribution than drug-discovery rights.

Potential deal structures include:

1. Regional commercialization rights for an approved mepivacaine cartridge.
2. Contract manufacturing agreements with dental-anesthetic specialists.
3. Private-label supply for dental distributors.
4. Device and cartridge technology licenses.
5. Co-development of preservative-free local-anesthetic products.
6. Portfolio licensing that combines plain mepivacaine with epinephrine-containing anesthetics.

A licensee should prioritize territories where dental anesthetic supply is fragmented, regulatory registrations are costly, or incumbent brands have limited distribution.

What is the FDA regulatory status of Scandonest Plain?

Scandonest Plain is an FDA-regulated prescription local anesthetic injection marketed for dental use. The US labeling identifies mepivacaine hydrochloride injection in a 3% strength and describes its single-use dental cartridge presentation. [1]

The regulatory pathway for a competing product depends on the reference listing, product-specific FDA requirements, and whether the competitor qualifies for an abbreviated application or must submit a different application. The principal technical burden is demonstrating pharmaceutical equivalence, bioequivalence where applicable, microbiological quality, container-closure integrity, and manufacturing compliance.

Because the product is an injectable, FDA review will focus heavily on quality and manufacturing controls rather than on excipient innovation alone.

How should a company value the Scandonest Plain opportunity?

The opportunity is best assessed as a mature injectable platform with modest formulation-development risk and meaningful execution risk.

Value driver	Assessment
Active-ingredient exclusivity	Low
Formulation complexity	Low to moderate
Sterile manufacturing complexity	High
Device and cartridge dependence	High
Regulatory development risk	Moderate
Price erosion risk	High after multiple generic entries
Brand retention potential	Moderate if supply and dentist loyalty are strong
Patent-driven pricing power	Low
Licensing potential	Moderate in regional markets
Best differentiation	Preservative-free, sulfite-free, vasoconstrictor-free, reliable cartridge supply

Revenue exposure depends on procedure volume, distributor contracts, dental market share, and the number of interchangeable competitors. The strongest commercial case is a cost-efficient, high-quality product with consistent supply, not an expensive reformulation supported by weak clinical differentiation.

Key Takeaways

• Scandonest Plain is a 3% mepivacaine hydrochloride dental injection without epinephrine.
• Its formulation uses a deliberately minimal excipient system centered on sodium chloride and water for injection.
• Preservatives, sulfites, and vasoconstrictors would weaken the product's core market position.
• Mepivacaine's age means that molecule-level patent exclusivity is not the primary commercial barrier.
• Generic entry risk is high, but sterile dental-cartridge manufacturing limits the field of capable competitors.
• The strongest opportunities are cartridge optimization, supply reliability, regional licensing, private-label manufacturing, and specialty positioning.
• Patent value is more likely to reside in packaging, container closure, manufacturing, or delivery systems than in the basic formulation.
• FDA regulatory success will depend on injectable-product quality, sterility, container compatibility, and manufacturing control.

FAQs

Is Scandonest Plain sulfite-free?

Yes. The plain product is designed without epinephrine, eliminating the usual need for sulfite antioxidants used to stabilize vasoconstrictor-containing dental anesthetics. Product-specific labeling should control the final determination. [1]

Can a competitor use a different tonicity agent?

Potentially, but the alternative would require support for safety, stability, osmolality, injection tolerability, and regulatory comparability. Retaining sodium chloride is usually the lower-risk strategy.

Is Scandonest Plain a biologic or biosimilar product?

No. Mepivacaine hydrochloride is a conventional small-molecule active ingredient. Biosimilar pathways do not apply.

Can a cartridge design support patent protection?

Yes. A novel cartridge, plunger, closure, syringe interface, or packaging system may support patent protection if it satisfies applicable novelty, nonobviousness, and other legal requirements. The protection would cover the delivery system rather than the established mepivacaine molecule.

What is the most defensible commercial position for a generic Scandonest Plain product?

A preservative-free, sulfite-free, vasoconstrictor-free 3% mepivacaine cartridge with dependable supply, compatible dental hardware, competitive pricing, and strong quality documentation offers the clearest position.

References

1. U.S. Food and Drug Administration. (n.d.). Scandonest Plain 3%: Mepivacaine hydrochloride injection, USP, prescribing information. Septodont. https://www.accessdata.fda.gov/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
3. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
4. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. https://www.ich.org/page/quality-guidelines
5. International Council for Harmonisation. (2020). Q3E: Guideline for extractables and leachables. https://www.ich.org/page/quality-guidelines